Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)

Next Previous
Trial Profile

A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Pembrolizumab (Primary) ; TIDAL-01 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Acronyms STARLING
  • Sponsors Turnstone Biologics

Most Recent Events

  • 04 Feb 2025 Status changed from recruiting to discontinued.
  • 14 Aug 2024 Positive initial data from metastatic colorectal cancer at data cutoff date of July 15, 2024 presented in a Turnstone Biologics Media Release.
  • 21 Mar 2024 According to Turnstone Biologics Corp, initial clinical update across these trials in mid-2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top